Director of R&D Implementation and International Operations at OralCDx - Montebello, New York, United States
OralCDx is a brush used to test the common white or red spots found in many people's mouths at one time or another. While many of these spots are benign, caused by a sharp tooth or a hot drink, about 3% of them can contain precancerous cells. Undetected, these cells will develop into oral cancer, but if they are found, these spots can be removed long before they can cause harm. Oral cancer is a disease that kills as many Americans as melanoma, twice as many as cervical cancer, and is rising among women, young people and non-smokers. Well over 25% of those found to have oral cancer do not use tobacco or abuse alcohol. Recent studies have also shown a link between HPV and an increase in oral cancer. The accuracy of OralCDx was demonstrated in one of the largest studies in oral medicine ever conducted, performed at 35 academic centers in the U.S., involving nearly 1,000 patients. This study was published as the cover story of the Journal of the American Dental Association and earned OralCDx the ADA's prestigious Seal of Acceptance. CDx Diagnostics, the maker of OralCDx, is the world's leader in the prevention of cancer of the oral cavity, pharynx, larynx and esophagus through detection of their precancerous precursors. These proprietary, life saving CDx tests are nationally available to primary care physicians, gastroenterologists, otolaryngologists, oral surgeons, periodontists, and dentists. Additional info can be found at http://www.cdxdiagnostics.com.